Wells Fargo & Company Boosts uniQure (NASDAQ:QURE) Price Target to $75.00

uniQure (NASDAQ:QURE) had its target price increased by research analysts at Wells Fargo & Company from $60.00 to $75.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 71.90% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Barclays decreased their target price on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday. HC Wainwright upped their price objective on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research report on Tuesday, May 5th. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Finally, Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Performance

Shares of QURE opened at $43.63 on Thursday. The company’s 50 day simple moving average is $37.49 and its 200-day simple moving average is $26.25. The firm has a market cap of $3.03 billion, a PE ratio of -10.88 and a beta of 0.90. uniQure has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.01, a quick ratio of 10.40 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. During the same quarter last year, the company earned ($0.69) EPS. As a group, equities analysts predict that uniQure will post -3.44 EPS for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 164,429 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the transaction, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This represents a 22.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director owned 43,254 shares of the company’s stock, valued at $1,949,025.24. The trade was a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 433,229 shares of company stock valued at $17,944,799 over the last ninety days. 4.65% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Large investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the period. Aberdeen Group plc lifted its position in shares of uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the period. State Street Corp boosted its stake in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its stake in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.